NKTR vs VLTO · rev $21.0M vs P/E 29, rev $5.50B
Nektar Therapeutics (NKTR) versus Veralto Corporation (VLTO) — a side-by-side from cached financials, not a winner call.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Veralto Corporation (VLTO) is a pollution & treatment controls company listed on US.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
Latest reported VLTO revenue for 2025-12-31 was $5.50B. Net income was $940.0M. Revenue was up 6.0% from 2024-12-31 to 2025-12-31. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
NKTR currently screens at market cap $307.2M. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
Not investment advice. Open the NKTR and VLTO stock pages for the full models.
Not investment advice.